<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00091104</url>
  </required_header>
  <id_info>
    <org_study_id>040251</org_study_id>
    <secondary_id>04-C-0251</secondary_id>
    <secondary_id>NCI-6974</secondary_id>
    <secondary_id>CDR0000383246</secondary_id>
    <nct_id>NCT00091104</nct_id>
    <nct_alias>NCT00088439</nct_alias>
  </id_info>
  <brief_title>Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma</brief_title>
  <official_title>A Study in Metastatic Melanoma Using a Lymphodepleting Conditioning Followed by Infusion of Anti-MART-1 TCR-Gene Engineered Lymphocytes and Subsequent Peptide Immunization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institutes of Health Clinical Center (CC)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Inserting a laboratory-treated gene into a person's white blood cells may make the&#xD;
      body build an immune response to kill tumor cells. Giving cyclophosphamide and fludarabine&#xD;
      before a white blood cell infusion may suppress the immune system and allow tumor cells to be&#xD;
      killed. Vaccines may make the body build an immune response to kill tumor cells. Aldesleukin&#xD;
      may stimulate a person's white blood cells to kill tumor cells. Combining white blood cell&#xD;
      infusion with vaccine therapy and aldesleukin may cause a stronger immune response and kill&#xD;
      more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of gene-modified white&#xD;
      blood cells when given together with cyclophosphamide, fludarabine, vaccine therapy, and&#xD;
      aldesleukin and to see how well it works in treating patients with metastatic melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the safety of peripheral blood lymphocytes (PBLs) retrovirally transduced with&#xD;
           an anti-MART-1 T-cell receptor (TCR) gene followed by high-dose aldesleukin (IL-2) and&#xD;
           MART-1:27-35 peptide vaccine in patients with HLA-A*0201-positive metastatic melanoma&#xD;
           receiving a myeloablative preparative regimen comprising cyclophosphamide, fludarabine&#xD;
           phosphate, and total-body irradiation.&#xD;
&#xD;
        -  Determine, preliminarily, whether antitumor antigen TCR-engineered tumor-infiltrating&#xD;
           lymphocytes or PBLs followed by IL-2 and MART-1:26-35 after a nonmyeloablative but&#xD;
           lymphoid-depleting preparative regimen will result in clinical tumor regression in these&#xD;
           patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the in vivo survival of TCR gene-engineered cells from these patients.&#xD;
&#xD;
        -  Evaluate, preliminarily, clinical response in these patients.&#xD;
&#xD;
      OUTLINE: Patients with resectable tumor undergo tumor biopsy. Tumor-infiltrating lymphocytes&#xD;
      (TILs) from the tumor sample are cultured in vitro and tested for reactivity to melanoma&#xD;
      antigens. Patients who are unable to undergo biopsy or whose TILs do not grow in culture are&#xD;
      assigned to groups I or II. Patients whose tumors yield TILs that do not exhibit melanoma&#xD;
      reactivity are assigned to group III. Patients with TILs that exhibit melanoma reactivity are&#xD;
      removed from the study.&#xD;
&#xD;
        -  Autologous stem cell collection: Patients undergo stem cell collection on treatment&#xD;
           protocol NCI-03-C-0277 for reinfusion after the myeloablation and cell therapy. Patients&#xD;
           receive filgrastim (G-CSF) subcutaneously (SC) twice daily beginning on day 0 and&#xD;
           continuing for up to 5 days. Patients then undergo stem cell collection by apheresis or&#xD;
           bone marrow harvest beginning on day 5 and continuing for up to 3 days. Some patients&#xD;
           may receive a second course of G-CSF and undergo additional stem cell collection by&#xD;
           apheresis or undergo treatment as outlined in group II.&#xD;
&#xD;
        -  Group I (peripheral blood lymphocytes [PBLs] with myeloablative preparative regimen):&#xD;
           Patients receive a myeloablative preparative regimen comprising cyclophosphamide IV over&#xD;
           1 hour on days -7 and -6, fludarabine phosphate IV over 15-30 minutes on days -7 to -3,&#xD;
           and total-body irradiation twice daily on days -3 to -1. Patients also receive&#xD;
           autologous in vitro tumor-reactive, T-cell receptor (TCR) gene-transduced PBLs IV over&#xD;
           20-30 minutes on day 1 and aldesleukin IV over 15 minutes every 8 hours on days 1-5, and&#xD;
           G-CSF SC daily beginning on day 1 and continuing until blood counts recover.&#xD;
&#xD;
        -  Group II (PBLs with nonmyeloablative preparative regimen): Patients who do not meet the&#xD;
           eligibility criteria for group I receive a nonmyeloablative preparative regimen&#xD;
           comprising cyclophosphamide IV over 1 hour on days -7 and -6 and fludarabine phosphate&#xD;
           IV over 30 minutes on days -5 to -1. Patients then receive aldesleukin, and G-CSF as in&#xD;
           group I.&#xD;
&#xD;
        -  Group III (autologous transduced TILs): Patients who have resected tumors that yield&#xD;
           viable TILs have their TILs transduced with the anti-MART-1 TCR gene retroviral vector.&#xD;
           Patients receive cyclophosphamide and fludarabine phosphate as in group II. Patients&#xD;
           then receive autologous transduced TILs IV over 20-30 minutes on day 0. Patients also&#xD;
           receive G-CSF and high-dose aldesleukin as in group I.&#xD;
&#xD;
      All patients receive peptide immunizations with MART-1:27-35 peptide vaccine emulsified in&#xD;
      incomplete Freund's adjuvant SC on days 0-4, 11, 18, and 25.&#xD;
&#xD;
      In groups II or III, treatment may repeat once 6-8 weeks later for a total of 2 courses in&#xD;
      the absence of disease progression or unacceptable toxicity. Treatment may consist of the&#xD;
      first type cell infusion or patients may crossover to receive the other cell infusion (PBLs&#xD;
      vs TILs).&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically for at least 5 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 136 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor regression</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>In vivo survival of transplanted cells</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">136</enrollment>
  <condition>Melanoma (Skin)</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MART-1:27-35 peptide vaccine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>incomplete Freund's adjuvant</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic autologous lymphocytes</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic tumor infiltrating lymphocytes</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous hematopoietic stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>in vitro-treated peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>total-body irradiation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of metastatic melanoma&#xD;
&#xD;
          -  HLA-A*0201-positive disease&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  Refractory to standard therapy, including high-dose aldesleukin therapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,000/mm^3&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin &gt; 8.0 g/dL&#xD;
&#xD;
          -  Lymphocyte count &gt; 500/mm^3&#xD;
&#xD;
          -  WBC &gt; 3,000/mm^3&#xD;
&#xD;
          -  No coagulation disorder&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  ALT and AST &lt; 3 times upper limit of normal&#xD;
&#xD;
          -  Bilirubin ≤ 2.0 mg/dL (&lt; 3.0 mg/dL for patients with Gilbert's disease)&#xD;
&#xD;
          -  Hepatitis B antigen negative&#xD;
&#xD;
          -  Hepatitis C antibody negative (unless antigen negative)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.6 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No myocardial infarction&#xD;
&#xD;
          -  No cardiac arrhythmias&#xD;
&#xD;
          -  No cardiac ischemia&#xD;
&#xD;
          -  LVEF ≥ 45% by stress cardiac test* (for patients ≥ 50 years of age OR those with a&#xD;
             history of EKG abnormalities)&#xD;
&#xD;
          -  No other major cardiovascular illness by stress thallium or comparable test NOTE:&#xD;
             *Stress thallium, stress MUGA, dobutamine echocardiogram, or other stress test&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No major respiratory illness&#xD;
&#xD;
          -  No obstructive or restrictive pulmonary disease&#xD;
&#xD;
          -  FEV_1 ≥ 60% of predicted on pulmonary function test*&#xD;
&#xD;
          -  DLCO ≥ 60% predicted (for total-body irradiation cohort) NOTE: *For patients with a&#xD;
             prolonged history of cigarette smoking or symptoms of respiratory dysfunction&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No major immune system illness&#xD;
&#xD;
          -  No active systemic infection or opportunistic infection&#xD;
&#xD;
          -  No primary immunodeficiency (e.g., autoimmune colitis or Crohn's disease)&#xD;
&#xD;
          -  No secondary immunodeficiency (e.g., due to chemotherapy or radiotherapy)&#xD;
&#xD;
          -  No history of severe immediate hypersensitivity reaction to study drugs&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 4 months after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  Must sign a durable power of attorney&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from prior immunotherapy&#xD;
&#xD;
          -  Prior immunization to melanoma antigens allowed&#xD;
&#xD;
               -  Progressive disease during prior immunization allowed&#xD;
&#xD;
          -  Prior cellular therapy, including vector transduction with or without myeloablation,&#xD;
             allowed&#xD;
&#xD;
          -  More than 6 weeks since prior anticytotoxic T-lymphocyte-associated antigen-4 (CTLA-4)&#xD;
             monoclonal antibody (MDX-010) therapy&#xD;
&#xD;
          -  No prior anti-CTLA-4 antibody unless a post anti-CTLA-4 antibody treatment colonoscopy&#xD;
             was normal by biopsy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Recovered from prior chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  No concurrent systemic steroids&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Recovered from prior radiotherapy&#xD;
&#xD;
          -  No prior significant mediastinal or lung radiation (for total-body irradiation cohort)&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 4 weeks since prior systemic therapy and recovered&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven A. Rosenberg, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NCI - Surgery Branch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NCI - Surgery Branch</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>September 7, 2004</study_first_submitted>
  <study_first_submitted_qc>September 7, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2004</study_first_posted>
  <last_update_submitted>March 14, 2012</last_update_submitted>
  <last_update_submitted_qc>March 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2012</last_update_posted>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Freund's Adjuvant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

